(Q35827559)

10 August 2017

Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients (English)

1 reference

10 August 2017

1 reference

Sofia A Pereira

1

1 reference

10 August 2017

Teresa Branco

2

1 reference

10 August 2017

Rita M Côrte-Real

3

1 reference

10 August 2017

Isabel Germano

4

1 reference

10 August 2017

Fátima Lampreia

5

1 reference

10 August 2017

Umbelina Caixas

6

1 reference

10 August 2017

Emília C Monteiro

7

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

British Journal of Clinical Pharmacology

10 August 2017

1 reference

10 August 2017

61

1 reference

10 August 2017

5

1 reference

10 August 2017

601-604

1 reference

Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1

10 August 2017

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885052

In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes.

11 July 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885052

Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients

11 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02619.X

Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02619.X

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02619.X

The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism.

21 January 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885052

10.1111/J.1365-2125.2006.02619.X

24 September 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

16669853

1 reference